Sodium–glucose cotransporter-2 (SGLT2) inhibitors are also very attractive drugs as they reduce the rate of adverse cardiovascular outcome and mortality in T2D patients [55]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.